Alessandro Bartoloni to Janus Kinase Inhibitors
This is a "connection" page, showing publications Alessandro Bartoloni has written about Janus Kinase Inhibitors.
Connection Strength
0.139
-
Compassionate use of JAK1/2 inhibitor ruxolitinib for severe COVID-19: a prospective observational study. Leukemia. 2021 04; 35(4):1121-1133.
Score: 0.139
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.